U.S. Pharmacist Weekly News

September 21, 2022

Pharmacist Intervention Brings Down BP for Montana Patients

Having pharmacists work collaboratively with nurses and primary care physicians resulted in a very significant improvement in hypertension for some Montana patients. A new study presented at the American Heart Association Hypertension 2022 Scientific Sessions and published in the journal Hypertension discussed how an expanded scope of practice can lead to those types of opportunities. Read more.

Younger Children Can Accurately Swab Themselves for COVID-19 Tests

Children returning to in-classroom learning during the COVID-19 pandemic must be tested frequently. The problem is a shortage of healthcare workers to do that. A new study published in the Journal of the American Medical Association offers an unexpected solution: finding that self-swabbing results performed by kids aged younger than 14 years was comparable with those from healthcare workers. Read more.

Study: Tpoxx Treatment for Monkeypox Well-Tolerated

With more than 22,000 cases of monkeypox confirmed in the United States, the lack of FDA-approved treatments is a growing problem. Find out how a review of adverse events led CDC researchers to conclude that tecovirimat (Tpoxx) might be the safest option—even if their review could not yet confirm small studies suggesting effectiveness in humans.

New Guidance Issued on Treatment of Glucocorticoid-Induced Osteoporosis

Updated guidelines on how to treat osteoporosis caused by glucocorticoid use offers new recommendations on the use of abaloparatide and romosozumab, which have come on the market since the previous version in 2017. The updated guidance was recently issued by the American College of Rheumatology, recognizing that patients using glucocorticoid medications for inflammatory conditions risk developing osteoporosis. Read more.